A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.
Long-term results of the POET* trial have suggested that patients with left-sided infective endocarditis (IE) could safely switch from conventional intravenous (IV) antibiotics to oral antibiotics, with oral antibiotics associated with a reduced mortality risk.
In intravenous drug users, hospital admissions for infective endocarditis (IE) appear to be on the rise, with the prevailing treatment approach shifting away from surgical to medical, according to a new study presented at the recently concluded 68th Annual Scientific Session & Expo of the American College of Cardiology (ACC 2019).
The tetracycline omadacycline is not inferior to moxifloxacin when used as empirical monotherapy for hospitalized adults with community-acquired bacterial pneumonia, according to the results of a phase III study.
The aminoglycoside plazomicin has demonstrated noninferiority to meropenem, a broad-spectrum carbapenem antibiotic, for treating complicated urinary tract infection (UTI) and acute pyelonephritis, with the former yielding greater microbiologic eradication as reflected by lower incidences of recurrence and relapse, according to data from the phase III EPIC* trial.
Combination treatment with glecaprevir plus pibrentasvirproduces a sustained virological response in more than 90 percent of hepatitis C virus (HCV)-infected patients who previously failed direct-acting antiviral (DAA) treatments, regardless of liver fibrosis stage, a study has shown.
Scientists from the Department of Microbiology, University of Hong Kong (HKU) recently discovered a compound with broad antiviral activity against viruses causing Middle East Respiratory Syndrome (MERS), avian flu (H7N9), severe acute respiratory syndrome (SARS) and Zika fever.